Benign Prostatic Hyperplasia Market: By Diagnosis Test, Digital Rectal Examination and Others; By Treatment Procedures; By Geography - Forecast 2018 to 2023

Benign Prostatic Hyperplasia (BPH) refers to a physical condition in men, which leads to the proliferation of prostatic stromal cells in a non-cancerous way that results in an enlarged prostate gland. Benign prostatic hyperplasia (BPH) is also referred as benign prostatic hypertrophy or benign prostatic obstruction. Owing to the factors such as lack of physical exercise, erectile dysfunction, medical conditions such as obesity, heart and circulatory disease and type2 diabetes are propelling the growth of the market. Moreover, family history of benign prostatic
Hyperplasia and men aged 40 years and above are more prone to the BPH disorder.

The Global Benign Prostatic Hyperplasia (BPH) are classified on the basis of various parameters. On the basis of symptoms the market is classified into Difficulty in Bladder Emptying, Frequent Urination, Straining, Post Urination Dribbling or Weak Stream and Others. On the basis of diagnosis the market is segmented into Prostate-Specific Antigen (PSA) Test, Digital Rectal Examination (DRE) and Others. Based on treatment procedures the market is segregated into Medical Therapies, Surgical Therapies, Minimally Invasive Therapies, Laser Surgical Therapies, Needle Ablation and Others.

GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) MARKET VALUE, 2016-2023 ($M)

In terms of Geography, the global Benign Prostatic Hyperplasia (BPH) market is classified into North America, Europe, APAC and Row. North America is expected to be the major player in the Benign Prostatic Hyperplasia (BPH) market followed by Asia Pacific. Asia-Pacific is projected to witness the highest growth during the forecast period having the emerging countries such as China, India and Japan in this region.
Key market players in the global Benign Prostatic Hyperplasia (BPH) market include companies such as Astellas Pharma (Japan), Eli Lilly (U.S.), GlaxoSmithKline (U.K), Sanofi (France) and few others.